Scarica l'app Stockscreener
11.62
0.27%
0.0402
Contineum Therapeutics Inc Borsa (CTNM) Ultime notizie
EBITDA per share of Contineum Therapeutics, Inc. – NASDAQ:CTNM - TradingView — Track All Markets
Great Week for Contineum Therapeutics, Inc. (NASDAQ:CTNM) Institutional Investors After Losing 5.3% Over the Previous Year - 富途牛牛
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Contineum Therapeutics Inc trading resumes - MSN
Contineum Therapeutics Prices Upsized $90 Million Class A Share Offering - marketscreener.com
Contineum Therapeutics stock drops as company prices upsized $90 million offering - MSN
Contineum prices upsized public offering of common stock at $12.25 per share - Investing.com Nigeria
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Contineum Therapeutics prices upsized $90 million public offering at $12.25 per share - marketscreener.com
Contineum Therapeutics (NASDAQ: CTNM) sets price for upsized $90.0M offering - Stock Titan
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering - Business Wire
Contineum Therapeutics launches $75 million public offering of stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics launches $75 million public offering of stock - Investing.com
Contineum Therapeutics announces proposed $75M public offering - MSN
Contineum Therapeutics falls on planned $75 million share sale - TradingView — Track All Markets
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - TipRanks
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering - Business Wire
ETFs Investing in Contineum Therapeutics, Inc. Stocks - TradingView — Track All Markets
Contineum Therapeutics, Inc. (NASDAQ:CTNM) institutional owners may be pleased with recent gains after 16% loss over the past year - simplywall.st
Saturn V Capital Management LP Has $1.27 Million Stock Holdings in Contineum Therapeutics, Inc. $CTNM - MarketBeat
Will Contineum Therapeutics Inc. stock rally after Fed decisionsWeekly Profit Recap & Daily Oversold Stock Bounce Ideas - Newser
Contineum Therapeutics, Inc. $CTNM Shares Purchased by Franklin Resources Inc. - MarketBeat
Critical Survey: BioMarin Pharmaceutical (NASDAQ:BMRN) & Contineum Therapeutics (NASDAQ:CTNM) - Defense World
Aug Volume: How risky is Contineum Therapeutics Inc. stock now2025 Geopolitical Influence & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Support Test: Why Contineum Therapeutics Inc. stock attracts high net worth investorsMarket Performance Recap & Technical Analysis for Trade Confirmation - moha.gov.vn
CTNMContineum Therapeutics Latest Stock News & Market Updates - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Price Target Lowered to $14.00 at Robert W. Baird - Defense World
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference - BioSpace
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - Nasdaq
Contineum MS drug stumbles in mid-stage trial - Indian Pharma Post
CTNM: Analyst Baird Lowers Price Target to $14.00 but Maintains Outperform Rating | CTNM Stock News - GuruFocus
Royal Bank Of Canada Has Lowered Expectations for Contineum Therapeutics (NASDAQ:CTNM) Stock Price - Defense World
Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from RBC Capital - The Globe and Mail
RBC Capital Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - Nasdaq
Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis - marketscreener.com
Contineum’s MS drug falls short in Phase II trial - Yahoo Finance
Contineum’s PIPE-307 misses in midstage MS study - BioWorld MedTech
Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value - Benzinga
Stifel maintains Buy rating on Contineum Therapeutics stock despite MS trial failure - Investing.com Canada
Contineum’s PIPE-307 Fails Phase II MS Trial, Focus Shifts To IPF Candidate - Citeline News & Insights
RBC Capital Lowers Price Target for Contineum Therapeutics (CTNM) | CTNM Stock News - GuruFocus
RBC Capital Lowers Price Target for Contineum Therapeutics (CTNM - GuruFocus
RBC Lowers Price Target on Contineum Therapeutics to $22 From $25, Keeps Outperform, Speculative Risk - MarketScreener
Contineum falls after missing main goals in multiple sclerosis trial - Seeking Alpha
Contineum stock down after MS drug fails in trial - The Pharma Letter
J&J, Contineum Fail ‘Risky’ Mid-Stage Multiple Sclerosis Trial - BioSpace
A look into Contineum Therapeutics Inc (CTNM)’s deeper side - Setenews
Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback - TipRanks
Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF - TipRanks
A brain biotech’s top drug fails against MS - BioPharma Dive
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - BioSpace
Stocks to Watch: Contineum, Gap Inc., Geospace Technologies - 富途牛牛
Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments - TipRanks
Contineum’s multiple sclerosis drug fails to meet efficacy endpoints By Investing.com - Investing.com
Contineum stock falls after multiple sclerosis drug fails in trial By Investing.com - Investing.com Australia
Contineum Therapeutics reports topline data from its phase 2 Pipe-307 Vista trial for the treatment of relapsing-remitting Multiple Sclerosis - marketscreener.com
Contineum stock falls after multiple sclerosis drug fails in trial - Investing.com
0.42%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):